Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Depression
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Depression
    Duloxetine, SSRIs Produce Similar Rates of Sexual Dysfunction in Patients With Depression: Presented at WCBP - (DGDispatch)
    TopAbstracts in Depression 07/01/2009 - (DGNews)
    Desvenlafaxine Reduces Anxiety Associated With Major Depressive Disorder: Presented at WCBP - (DGDispatch)
    Desvenlafaxine Is Effective for Major Depressive Disorder: Presented at WCBP - (DGDispatch)
    Armodafinil Improves Excessive Sleepiness Associated With Treated Obstructive Sleep Apnoea in Patients With Depression: Presented at ENS - (DGDispatch)

    News archive

     Recent webcasts/CME - Depression
      Treatment-Resistant Depression -- Part III: Switching Antidepressants vs. Conventional Augmentation Strategies
      On the Front Line of Major Depressive Disorder and Comorbidities: Managed Care and the Primary Care Physician
      Treatment-Resistant Depression -- Part II: Augmentation Strategies
      Treatment-Resistant Depression -- Part I: Introduction and Clinical Presentations
      Enhancing Treatment for Patients with Comorbid Depression, Diabetes and Heart Disease

      Webcasts/CME archive

       Recent cases - Depression
        Creutzfeldt-Jacob Disease Presenting as Severe Depression: A Case Report
        Sexual Dysfunction in a Young Mother
        Psychiatric Disorder Associated with Vacuum-Assisted Breast Biopsy Clip Placement: A Case Report
        A Postmenopausal Woman Presenting with Ekbom Syndrome Associated with Recurrent Depressive Disorder: A Case Report
        Affective Psychosis, Hashimoto's Thyroiditis, and Brain Perfusion Abnormalities: Case Report

        Cases archive
          




        my personal edition > depression > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Eszopiclone (Lunesta) With Fluoxetine (Prozac) Improves Comorbid Insomnia in Depression

        By Bruce Sylvester

        ATLANTA, GA -- May 30, 2005 -- Combination treatment with eszopiclone (Lunesta) and fluoxetine (Prozac) is well tolerated and achieves both rapid and sustained improvements in sleep and daytime symptoms in depressed patients with comorbid insomnia, researchers report.

        Lead author Daniel Buysse, MD, Professor of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States, presented the findings here on May 25th at the American Psychiatric Association (APA) Annual Meeting.

        "Eczopiclone effectively treats insomnia associated with major depression, is well tolerated and, very importantly, does not interfere with the antidepressant effect of concurrently administered fluoxetine," Dr. Buysse said.

        The investigators enrolled 545 subjects diagnosed with major depression and insomnia according to Diagnostic and Statistical Manual -- Revision IV criteria. For insomnia, patients showed sleep latency of 30 minutes or more (median 74 minutes), wake time after sleep onset of 45 minutes or more (median 90 minutes), and total sleep time of 390 minutes or less (median 294 minutes).

        All subjects received fluoxetine 20 mg each morning and were randomized to 8 weeks of double-blind treatment with either eszopiclone 3 mg or placebo daily at bedtime. The researchers assessed subjects weekly for subjective sleep and daytime function data..

        Eszopiclone subjects achieved significantly shorter sleep latency and greater total sleep time at each treatment week (P < .03) compared to placebo subjects, and they achieved significantly shorter wake time after sleep onset at weeks 1, 3-5, and 7-8 (P < .04).

        Eszopiclone subjects also achieved higher scores for sleep quality and depth throughout the study (P < .005), and higher ratings for daytime alertness, ability to concentrate, and well-being (P +/- .02).

        "The rapid sleep improvement with adjunctive eszopiclone may be important, given the relatively slower onset of antidepressant effects with selective serotonin reuptake inhibitors," the authors noted.

        Dr. Buysse said, "This is the first study of an insomnia drug conducted in this way and for this population of comorbid patients. It remains to be seen if other drugs of the same class would have the same effect."

        The study was supported by Sepracor, Inc.


        [Presentation title: Adjunctive Eszopiclone With Fluoxetine for MDD and Insomnia: Sleep Effects. Abstract NR558]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send